問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei WanFang Hospital (Managed by Taipei Medical Univeristy) (在職)

Division of Orthopedics

Division of Radiation Therapy

Taipei Medical University Hospital (在職)

Division of Others-Pathology

Division of Thoracic Medicine

Taichung Veterans General Hospital

Division of General Surgery

Linkou Chang Gung Medical Foundation

Division of Pediatrics

更新時間：2025-12-16

陳志榮Chen, Chi-Long
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳志榮

List

31Cases

2018-06-01 - 2024-12-31

Phase III

Completed
A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children

  • Condition/Disease

    Enterovirus 71 (EV71)

  • Test Drug

    nactivated EV71 whole viral particles adjuvanted with aluminum (Al(OH)3)

Participate Sites
7Sites

Terminated7Sites

2013-09-01 - 2014-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2013-09-01 - 2014-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2015-12-01 - 2016-12-30

Phase III

A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects with Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms

  • Condition/Disease

    Acute Hematogenous Osteomyelitis

  • Test Drug

    daptomycin (CUBICIN)

Participate Sites
5Sites

Terminated5Sites

2019-09-07 - 2021-01-26

Phase II

A Two-Part Study With a Birth Cohort (Observational Stage) for Early Diagnosis of Respiratory Syncytial Virus (RSV), Followed by an Optional Phase 2a, Randomized, Double-blind, Placebo-controlled Study (Interventional Stage) to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 in Infants With Acute Respiratory Tract Infection Due to RSV

  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    JNJ-53718678

Participate Sites
4Sites

Terminated4Sites

2014-03-01 - 2016-03-31

Phase II

An Open-Label, Dose-Finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Paediatric Subjects aged 3 to 6 years and 2 to 35 months old

  • Condition/Disease

    Prevention of Enterovirus 71 infection

  • Test Drug

    EV71 vaccine

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

黃高彬
China Medical University Hospital

Division of Pediatrics

2019-01-01 - 2020-12-31

Others

A Phase III Study of Immunogenicity and Safety Evaluation of AdimFlu-S (QIS) Quadrivalent Inactivated Influenza Vaccine in Healthy Subjects Aged 6 Months Old to 35 Months Old

  • Condition/Disease

    Influenza

  • Test Drug

    AdimFlu-S Quadrivalent Inactivated Influenza Vaccine(AdimFlu-S(QIS))

Participate Sites
9Sites

Recruiting8Sites

2007-09-26 - 2008-09-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2012-09-30 - 2015-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2017-05-15 - 2019-05-31

Others

Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563), in healthy infants starting at age 6-12 weeks.

  • Condition/Disease

    Active immunisation of infants against gastroenteritis (GE) due to rotavirus (RV).

  • Test Drug

    HRV PCV-free vaccine

Participate Sites
6Sites

Terminated6Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB